Clinical trial
A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children
NCT00408395 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Observer-Blind, Randomized, Parallel Groups, Multicenter, Exploratory Clinical Study to Evaluate the Immunogenicity and Safety of One and Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine Versus Two 0.25 mL Intramuscular Doses of a Commercially Available Influenza Vaccine in Healthy Children
- Lead sponsor
- Novartis Vaccines
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2006
- Completion date
- August 31, 2007
- Enrollment
- 281 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
influenza